The world of cannabis is staring at a potential financial shakeup due to talk of the impending demise of the Internal Revenue Code, specifically 26 U.S. Code §280E. This section is known as a frustration to any business connected with the “trafficking” of Schedule I or Schedule II controlled substances.
26 U.S. Code §280E states that in case a trade or business consists of trafficking in controlled substances that are prohibited by Federal law or the law of any State in which the said trade or business is conducted, no deduction or credit shall be allowed to such an organization under this law. This means that companies dealing with substances like cannabis cannot reduce their taxable income by deducting the cost of goods sold or any business expenses, leading to high tax bills.
The particular sting for cannabis companies arises from the fact that while cannabis might be legal in various U.S. states, it remains classified as a Schedule I substance on a federal level. As a result, companies working with cannabis fall under the umbrella of “trafficking” and face the constraints of this restriction.
The potential repeal or revision of §280E has the power to significantly impact the financial dynamics of cannabis companies, potentially allowing them to operate similar to traditional businesses in how they file their taxes. The elimination of this law could indeed stimulate growth by reducing the tax burden, enabling companies to allocate resources to strategic initiatives rather than paying enormous tax bills.
However, this change doesn’t come without its own set of challenges. It would require pushing through complex legislative processes and battling deeply rooted prejudices associated with Schedule I substances. For more details on this issue see the article by Bricker & Graydon LLP on JD Supra.
Only time will tell whether this potential death knell for §280E becomes a reality, and in the meantime, it presents an evolving landscape for all stakeholders in the cannabis industry to watch closely.